111 related articles for article (PubMed ID: 10933885)
1. The decreased in vivo clearance of CYP2D6 substrates by CYP2D6*10 might be caused not only by the low-expression but also by low affinity of CYP2D6.
Fukuda T; Nishida Y; Imaoka S; Hiroi T; Naohara M; Funae Y; Azuma J
Arch Biochem Biophys; 2000 Aug; 380(2):303-8. PubMed ID: 10933885
[TBL] [Abstract][Full Text] [Related]
2. Functional analysis of CYP2D6.31 variant: homology modeling suggests possible disruption of redox partner interaction by Arg440His substitution.
Allorge D; Bréant D; Harlow J; Chowdry J; Lo-Guidice JM; Chevalier D; Cauffiez C; Lhermitte M; Blaney FE; Tucker GT; Broly F; Ellis SW
Proteins; 2005 May; 59(2):339-46. PubMed ID: 15726636
[TBL] [Abstract][Full Text] [Related]
3. CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability.
Nakamura K; Ariyoshi N; Yokoi T; Ohgiya S; Chida M; Nagashima K; Inoue K; Kodama T; Shimada N; Kamataki T
Biochem Biophys Res Commun; 2002 May; 293(3):969-73. PubMed ID: 12051754
[TBL] [Abstract][Full Text] [Related]
4. Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6.
Niwa T; Hiroi T; Tsuzuki D; Yamamoto S; Narimatsu S; Fukuda T; Azuma J; Funae Y
Brain Res Mol Brain Res; 2004 Oct; 129(1-2):117-23. PubMed ID: 15469888
[TBL] [Abstract][Full Text] [Related]
5. Expression of four rat CYP2D isoforms in Saccharomyces cerevisiae and their catalytic specificity.
Wan J; Imaoka S; Chow T; Hiroi T; Yabusaki Y; Funae Y
Arch Biochem Biophys; 1997 Dec; 348(2):383-90. PubMed ID: 9434752
[TBL] [Abstract][Full Text] [Related]
6. Two novel CYP2D6*10 haplotypes as possible causes of a poor metabolic phenotype in Japanese.
Matsunaga M; Yamazaki H; Kiyotani K; Iwano S; Saruwatari J; Nakagawa K; Soyama A; Ozawa S; Sawada J; Kashiyama E; Kinoshita M; Kamataki T
Drug Metab Dispos; 2009 Apr; 37(4):699-701. PubMed ID: 19158312
[TBL] [Abstract][Full Text] [Related]
7. Expression, purification, biochemical characterization, and comparative function of human cytochrome P450 2D6.1, 2D6.2, 2D6.10, and 2D6.17 allelic isoforms.
Yu A; Kneller BM; Rettie AE; Haining RL
J Pharmacol Exp Ther; 2002 Dec; 303(3):1291-300. PubMed ID: 12438554
[TBL] [Abstract][Full Text] [Related]
8. Molecular cloning, expression, and characterization of CYP2D17 from cynomolgus monkey liver.
Mankowski DC; Laddison KJ; Christopherson PA; Ekins S; Tweedie DJ; Lawton MP
Arch Biochem Biophys; 1999 Dec; 372(1):189-96. PubMed ID: 10562433
[TBL] [Abstract][Full Text] [Related]
9. The role of phenylalanine 483 in cytochrome P450 2D6 is strongly substrate dependent.
Lussenburg BM; Keizers PH; de Graaf C; Hidestrand M; Ingelman-Sundberg M; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2005 Oct; 70(8):1253-61. PubMed ID: 16135359
[TBL] [Abstract][Full Text] [Related]
10. G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese.
Wang SL; Lai MD; Huang JD
Drug Metab Dispos; 1999 Mar; 27(3):385-8. PubMed ID: 10064570
[TBL] [Abstract][Full Text] [Related]
11. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
Arneth B; Shams M; Hiemke C; Härtter S
Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
[TBL] [Abstract][Full Text] [Related]
12. Dopamine formation from tyramine by CYP2D6.
Hiroi T; Imaoka S; Funae Y
Biochem Biophys Res Commun; 1998 Aug; 249(3):838-43. PubMed ID: 9731223
[TBL] [Abstract][Full Text] [Related]
13. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6.
Yu A; Dong H; Lang D; Haining RL
Drug Metab Dispos; 2001 Nov; 29(11):1362-5. PubMed ID: 11602510
[TBL] [Abstract][Full Text] [Related]
14. Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57).
Sakuyama K; Sasaki T; Ujiie S; Obata K; Mizugaki M; Ishikawa M; Hiratsuka M
Drug Metab Dispos; 2008 Dec; 36(12):2460-7. PubMed ID: 18784265
[TBL] [Abstract][Full Text] [Related]
15. A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function.
Oscarson M; Hidestrand M; Johansson I; Ingelman-Sundberg M
Mol Pharmacol; 1997 Dec; 52(6):1034-40. PubMed ID: 9415713
[TBL] [Abstract][Full Text] [Related]
16. Impaired expression of CYP2D6 in intermediate metabolizers carrying the *41 allele caused by the intronic SNP 2988G>A: evidence for modulation of splicing events.
Toscano C; Klein K; Blievernicht J; Schaeffeler E; Saussele T; Raimundo S; Eichelbaum M; Schwab M; Zanger UM
Pharmacogenet Genomics; 2006 Oct; 16(10):755-66. PubMed ID: 17001295
[TBL] [Abstract][Full Text] [Related]
17. Substrate-dependent functional alterations of seven CYP2C9 variants found in Japanese subjects.
Maekawa K; Harakawa N; Sugiyama E; Tohkin M; Kim SR; Kaniwa N; Katori N; Hasegawa R; Yasuda K; Kamide K; Miyata T; Saito Y; Sawada J
Drug Metab Dispos; 2009 Sep; 37(9):1895-903. PubMed ID: 19541829
[TBL] [Abstract][Full Text] [Related]
18. Influence of phenylalanine 120 on cytochrome P450 2D6 catalytic selectivity and regiospecificity: crucial role in 7-methoxy-4-(aminomethyl)-coumarin metabolism.
Keizers PH; Lussenburg BM; de Graaf C; Mentink LM; Vermeulen NP; Commandeur JN
Biochem Pharmacol; 2004 Dec; 68(11):2263-71. PubMed ID: 15498516
[TBL] [Abstract][Full Text] [Related]
19. Expression, purification, and biochemical characterization of a human cytochrome P450 CYP2D6-NADPH cytochrome P450 reductase fusion protein.
Deeni YY; Paine MJ; Ayrton AD; Clarke SE; Chenery R; Wolf CR
Arch Biochem Biophys; 2001 Dec; 396(1):16-24. PubMed ID: 11716457
[TBL] [Abstract][Full Text] [Related]
20. Functional characterization of human and cynomolgus monkey cytochrome P450 2E1 enzymes.
Hanioka N; Yamamoto M; Iwabu H; Jinno H; Tanaka-Kagawa T; Naito S; Shimizu T; Masuda K; Katsu T; Narimatsu S
Life Sci; 2007 Oct; 81(19-20):1436-45. PubMed ID: 17935737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
